Safe and Curative Brachytherapy Reirradiation with Organ-Sparing Hyaluronate Gel Injection by Kazushi Kishi et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
Safe and Curative Brachytherapy Reirradiation 
with Organ-Sparing Hyaluronate Gel Injection 
Kazushi Kishi, Yasutaka Noda and Morio Sato 
Wakayama Medical University, 
Japan 
1. Introduction 
In radiotherapy, sufficient dose delivery promises local cure [Hayashi, 2002; Okamoto, 2002; 
Wu, 2007] and reirradiation is as effective as the first radiotherapy. Dose dependency of the 
effect is also reported in reirradiation [Damast, 2010]. In the clinical situation, however, the use 
of reirradiation is limited because of the low tolerance level of surrounding normal tissue 
[Emami, 1991]. A significant incidence of late toxicity attributable to accumulated dose in 
various at-risk organs is reported [Salama, 2006; Wu, 2007]. In a survey of the attitudes of 
radiation oncologists, only one third (90 of 271) of participants responded that they would 
consider reirradiation for in-field failure after previous radical radiotherapy [Joseph, 2008]. 
Recent advancements in external beam radiation technology have enabled precision by 
beam set-up in image-guided radiotherapy (IGRT), accuracy in configuring dose 
distribution by intensity modified radiotherapy (IMRT), and adaptability to internal 
movements by real-time tracking techniques. However, surgery has been the only option for 
saving at-risk organs closely attached to the target. It is desirable to establish non-invasive 
or minimally invasive techniques for preserving these at-risk organs to enable safe and 
curative high-dose radiotherapy, even in the case of reirradiation. 
 For the purpose of reirradiation, we devised a minimally invasive procedure using a 
modern high-molecular-weight hyaluronate polymer gel, whereby a planned distance 
is created between the target and at-risk organs by injecting the gel (Fig. 1) [Kishi, 
2004、2006, 2007a, 2007b, 2009, Prada, 2007, 2009; Vordermark, 2008]. 
 
 
Fig. 1. An organ at risk (OAR) is displaced away from the zone of intensive irradiation 
(dotted circle) by the space created by an injected matrix. 
Target OAR Target OAR
Matrix
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In the first stage of our strategy, we aimed to treat recurrent disease requiring reirradiation 
with single-session high-dose-rate brachytherapy (HDRBT), reporting an effective decrease 
in estimated cumulative normal tissue complication probabilities (NTCP) to safer levels. In 
the second stage, we established this procedure for various difficult situations such as 
reirradiation of para-aortic lymphnode metastasis. 
2. Materials and methods 
2.1. Native-type hyaluronate as an injectable spacer 
2.1.1 Materials for injectable spacer 
Historically, saline, autologous blood, olive oil, dextrose, hyaluronate (hyaluronic acid: HA), 
alginate gels, gelatin hydrogel, polytetrafluoroethylene sheets, and many other others 
materials have been used for the purpose of separating various tissues. We have used 
injectable spacers for risk-organ preservation during brachytherapy since 2004 [Kishi, 2004, 
2007, 2007b]. Gel dissection has the features of both blunt dissection and hydrodissection, 
depending on its viscosity and the injection rate. Important considerations in selecting an 
injectable spacer include its chemical and biological inertness or activity, allergenicity, and 
the natural or artificial biodegradability of the material; the structure of the injected space is 
also an important factor, which is discussed later. 
2.1.2 Native-type hyaluronate molecules 
The numerous roles of innate hyaluronate in the body include as a supportive component of 
structure, lubrication in joints, tissue protection, and wound healing. Hyaluronate (also 
called hyaluronic acid or hyaluronan) is an anionic, nonsulfated macromolecular 
glycosaminoglycan, composed of repeated disaccharide units of glucuronic acid and N-
acetylglucosamine (Fig. 2), with a widely variable molecular weight. The native type is a 
single straight chain and exists widely, mainly as a constitutive molecule in the extracellular 
space of human and animal tissue. The molecular weight of constitutive hyaluronate is 
about three million Daltons. Degradation of hyaluronate occurs during inflammation and in 
the injury healing process, and also during bacterial infection. of innate or bacterial 
hyaluronidase to lower-molecular-weight hyaluronate and in further biodegradation. The 
degraded hyaluronate promotes tissue reactions. 
 
Fig. 2. Molecular structure of hyaluronate 
The known cellular surface receptors CD44, RHAMM (receptor for hyaluronic-acid-
mediated motility), and ICAM-1 (intercellular adhesion molecule-1) have hyaluronate 
binding sites that regulate cellular migration, proliferation, and inflammatory responses. 
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The binding activity is partially regulated by the molecular size of the hyaluronate: high-
molecular-weight hyaluronate (HMW-HA) acts to almost completely inhibit the above 
responses, while low-molecular-weight hyaluronate has a promotional effect. Recent reports 
state that HMW-HA inhibits the production of matrix metalloproteinases [Hashizume, 2010] 
as well as vascular leakiness [Singleton, 2010], and that there is a size function of 
hyaluronate [Wolny. 2010]. It may be speculated that a partially combined huge mass made 
of ligand masks itself until degradation to a size small enough to interact diffusely with the 
receptors, and which is constitutively maintained in normal tissue. In contrast, artificially 
cross-linked hyaluronate may have no or various features of this inhibition–promotion 
mechanism. 
In medical use, the effectiveness of native-type hyaluronate has been previously reported in 
the management of radiation dermatitis [41] [Primavera, 2006], in the prevention of 
postoperative adhesions in the pelvis [Kusunoki, 2005], and as antioxidant [Campo, 2008], 
depending on its molecular weight and concentration [Krasinski, 2009]. 
A high-molecular-weight hyaluronate that is commercially available for articular space 
injection (3.4 million Daltons of median molecular weight, 2.2 million of viscosity molecular 
size; Suvenyl, Chugai/Roche, Tokyo, Japan) is a non-animated native-type produced by 
genetically engineered bacterial fermentation. Its spacing effect generally lasts for a few to 
several hours depending on its concentration and the anatomic factors of the injected site. 
Contrast medium (5% Iopamiron 300mgI/ml, Bayer, Germany) is commonly added to saline 
mixture for visualization on X-ray CT images. Because its durability is concentration-
dependent, enriched gel is prepared on demand. 
2.2 Assessment of indication and eligibility 
To evaluate indications and the probability of effect and adverse effect, it is important to 
clarify previously irradiated doses and volumes in the involved at-risk organs, elapsed 
time after radiotherapy, and the present condition of the organs. In the case of no precise 
dose being available, a replicative simulation is required. According to published data, in 
most cases we may expect a certain degree of tissue recovery over the 6 months from the 
initial radiation [Abusaris, 2011; Nieder, 2006]. In addition to past history, the current 
status of at-risk organs is thought to be a significant determinant in assessing the 
vulnerability of the “recovered” status: hyperemia, edema, fibrosis, infection, hypoxia, 
atrophy, and other local pathophysiological conditions must be clarified and carefully 
interpreted. When any of these deteriorations is present, sufficient dose reduction is of 
greater importance.  
2.3 Techniques of image-guided interventions and radiotherapy 
2.3.1 Preparation of hyaluronate gel mixture 
Premedication: Because the procedure is minimally invasive, sedative premedication is not 
mandatory, and in most cases an ordinary meal is recommended the morning of treatment 
to promote relaxation in the patient. Anxiolytic use of hydroxyzine pamoate or similar is 
recommended. However, careful individual medical management is required throughout 
the procedure in frail patients.  
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Keeping the patient awake: in terms of safety and precision, it is helpful for the patient to be 
able to report sensation during crucial needle maneuvers and during injection of the gel; 
therefore, deep sedation is not recommended if avoidable.  
Use of sedatives: after completion of needle deployment, we recommend using 
benzodiazepam, which is effective in reducing post-traumatic psychological processing of 
the pain, anxiety, or fear immediately before and during the procedure.  
Monitoring: the patient is connected to ECG, respiration, oxygen saturation, and blood 
pressure monitors, and covered with sterile drapes on the X-ray CT couch. 
2.3.2 Needle deployment 
2.3.2.1 Procedure 
CT land marking and local anesthesia: puncture points are determined using the first set of 
plain CT images covering the target, and 10–20 ml of 1% lidocaine solution is then injected 
into the subcutaneous space at the intended puncture site. As well as superficial skin 
markings, tentative placement of a few 23 G needles inserted to a depth of 2–6 cm around 
the target as internal landmarks is useful in geometric planning to a deep target under X-ray 
CT guidance. 
We use Microselectron system applicator needles: 1.1 mm in external diameter and 8–20 cm 
in length. The applicator needles are inserted following the landmark needles and deployed 
under X-ray CT or real-time ultrasound guidance. The needles are advanced into (or 
minimally over, if necessary) the tumor and deployed as indicated. Fine-pitch (2 or 3 mm 
thick) X-ray CT images are then acquired and transferred to the treatment planning 
computer (Plato, Nucletron, Veenendaal, Netherlands).  
2.3.2.2 Special technical remarks regarding needle deployment 
a. Bone and perivertebral intervention: Bone involvement is common and is a leading 
cause of cancer pain, either sensory or neuropathic. It is generally not difficult to pierce 
the involved bone through a window in which the healthy bony structure has been lost, 
irrespective of the existence of a calcified zone. A drill (e.g., a 13-gauge bone biopsy 
needle: Osteosite Bone Biopsy Needle; Cook, Canada) may be required to gain access 
through hard bone surface. In case of perivertebral needle insertion beneath the pleura, 
subpleural gel injection produces a safe space for needle insertion avoiding pulmonary. 
b. Needle-tip-eye’s view: To negotiate a step-by-step safe path to a deep target, we build a 
scenario of what the needle-tip encounters (e.g., skin, subcutaneous adipose tissue, 
muscle fascia, muscle, inter-fascial adipose tissue, and possibly a nerve plexus) before 
reaching the target.  
c. Superficial lesions: We use a high-precision ultrasound system with 0.7 and 5.0 MHz 
(mostly 3.0-3.5 MHz) to examine superficial structures such as the dermis, epidermis, 
subcutaneous tissue, muscle, peritoneum, sub-fascial soft tissues, intestines, intestinal 
peristalsis, eyes, and vessels, as well as tumors; and to determine the infiltration range. 
d. Nerve plexus: The patient may experience suddenly increased pain when pressure from 
the needle insertion cause further stimulation to a nerve plexus. A swollen tumor 
causing pressure may be covered with a layer of irritated nerves; in this case, additional 
local anesthesia with lidocaine is generally effective. Use of denervative anesthesia with 
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phenol glycerol may be chosen here, but with the effect of masking future signals of 
local tumor recurrence. 
2.4 Hyaluronic gel injection 
2.4.1 Preparation 
The appropriate volume, concentration, and timing of injection of hyaluronic acid gel 
depends on the anatomical structure of the site and the required duration of spacing. Higher 
concentration provides spacing time. Most commonly, 50–150 mL of 1 mg/ml hyaluronic 
acid saline solution is prepared. A concentration of 1 mg/mL is sufficient for injection 
immediately before the start of irradiation, lasting in most cases from 30 minutes to 4 hours, 
depending on the site and structure of injection. 
2.4.2 Injection 
Injection into the space between the tumor and the risk organs is continued until a large 
enough thickness is obtained to create a margin of safety for the risk organ. If necessary, 
further injection is performed to maintain the space. Patency of the distance should be 
reconfirmed immediately before and after irradiation. 
2.4.3 Confirmation 
The space created by the injected gel is monitored by ultrasound or X-ray CT to check for 
unexpected gel migration and to measure the thickness of the gel space. 
2.5 Brachytherapy 
2.5.1 Trade-off principal 
The individual prescribed dose is generally a trade-off between the target dose and the dose 
to risk organs to avoid serious complications,. 
2.5.2 Treatment planning 
After contouring the target and surrounding critical organs, and recognizing the needle 
positions on the X-ray CT images imported into the planning computer, a treatment plan is 
created using 3D-inverse planning with graphic optimization (Plato version 13.7, 
Nucletron). 
2.5.3 Evaluation of dose–volume histogram 
We assessed the desirable separation distances between the target and the risk organs, 
applying calculated total dose of the risk organs [Burman, 1991]. The target dose, risk organ 
dose, separation distance, and each patient’s condition are individual trade-off factors. 
When it is difficult to prescribe the desirable dose, due to a low allowance for risk organ 
dose or due to difficulties encountered in creating a sufficient separation distance, the 
prescribed dose must be decreased and the distance recalculated step-by-step. 
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2.5.4 Estimation of equivalent dose 
Equivalent dose in a conventional 2-Gy fraction schedule is calculated using the linear–
quadratic (LQ) model and the linear–quadratic–linear (LQL) model [Astrahan, 2008], and is 
expressed as GyELQ2, α/┚ = 3 and GyE LQL2, α/┚ =3, transition dose (DT) = 6, respectively, where 
┙/┚ = 3 and DT = 6 for late effects of tumor and normal tissue. It should be noted that the 
LQ model may not provide a precise estimation for single-shot irradiation [Brenner, 2008; 
Kirkpatrick, 2008]. In the setting (┙/┚ = 3), each single fraction dose of 20, 18, and 16 Gy was 
calculated to have an equivalent total dose of 92.0, 75.6, and 60.6 Gy, respectively, in a 
conventional 2-Gy fraction schedule. 
2.6 Irradiation 
After determining an optimal set of prescribed dose and separation distance parameters, the 
planning data are then sent to a remote after-loader system (Microselectron HDR Ir-192 
version 2, Nucletron). In the present case series, a median dose of 18 Gy (range, 16–20 Gy) 
for GTV and a separation distance of not less than 1 cm was prescribed. The patient is 
moved to a shielded brachytherapy room and monitored by video-camera during the 
irradiation; vital data are also recorded. Irradiation generally takes 10–50 minutes, 
depending on the target size and dose. 
2.7 Recovery to discharge 
After the irradiation, we disconnect the patient from the monitoring equipment and remove 
the dwelling needles. Hemostasis is usually easy. The patient is moved to a couch to rest 
before being discharged. 
2.8 Evaluation and follow-up 
Patients are followed up at our outpatient clinic. Follow-up includes individual surveillance 
and management of adverse effects from the radiotherapy and the development of recurrent 
or metastatic disease. Tumor status and the patient’s general condition are evaluated 
regularly. The first tumor evaluation is usually done 2 to 3 months after treatment. Any 
signs or symptoms of radiation-induced late toxicity are recorded and graded according to 
the latest common terminology criteria for adverse events [Trotti, 2003]. Pregabalin alone or 
in combination with opioids may be effective for residual or radiation-induced neuropathic 
pain [O'Connor, 2009]. 
3. Summary of clinical effects in the first 30 patients 
We previously reported a series of 30 patients who were treated with reirradiation [Kishi, 
2009]. The patients had received previous irradiation with a median dose of 60 Gy (range, 
44–70 Gy) in 2-Gy fractions. All patients had subjective symptoms: 25 had pain, of which 21 
was refractory to analgesics, and 25 complained of a local mass of which 3 were ulcerated. 
By location, there were 13 head and neck lesions, 3 breast, and 10 abdominal wall lesions: 2 
each of bone, perineum, chest wall, intramuscular, and lymph nodal lesions; and 1 of the 
pelvic wall. Immediately before reirradiation, the median tumor (target) size was 4.0 cm 
(range, 2–13 cm), and median tumor volume was 18.8 cm3 (range, 2.4–646.7 cm3). 
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Of the 30 patients, 15 had locoregional recurrence of the primary disease and 10 had distant 
metastasis (of which 3 were incision disseminations and 5 were regional nodal relapse). By 
number of lesions at the time of reirradiation, 13 patients had one, 8 patients had two, 6 
patients had three, and 3 patients had four. The at-risk organs involved 29 skin areas, 4 
intestinal, 3 mucosal, and 3 retinal areas. The median dose to these at-risk organs in the 
previous radiotherapy was 50 Gy (range: 40–70 Gy) in 22–35 fractions. A single-fraction dose 
of 18.0 Gy (median, equivalent to 75.6 Gy at an / value of 3; range, 16–20 Gy) was 
prescribed to the tumor. The median created distance was 10 mm (range, 10–15 mm). 
Irradiation required approximately 10–50 minutes depending on the target size and dose. 
Gel injection resulted in a decrease in the dose to at-risk organs from 9.1  0.9 Gy to 4.4  0.4 
Gy (mean  standard deviation, p < 0.01), and the probability of normal tissue complications 
decreased from 60.8%  12.6% to 16.1%  19.8% (p < 0.01). We observed distinct tumor 
shrinkage in 20 of 21 eligible patients, including tumor disappearance in 6 patients; pain 
reduction in 18 of 21 eligible patients; and no unexpected late toxicity greater than grade 2. 
The median observation period was 19.5 months (range, 3–43 months). At the second 
month, a distinct decrease in tumor volume was observed in 20 (95%) of 21 eligible patients, 
including 6 (24%) of 25 eligible patients in whom the tumor had disappeared. 
4. Application to various body sites 
4.1 Head and neck reirradiation 
a. General skin and mucosal preservation 
Background: Prudent skin and mucosa preservation is generally required in reirradiation 
treatment for recurrent head and neck cancer after initial radiotherapy. The involved skin 
and mucosa can be moved away from the target when subcutaneous or submucosal gel 
injection is available. We can generally expect an additional distance of 1 cm or more, which 
will decrease the skin/mucosal dose by approximately 50% of that without HGI, and the 
thickness can easily be increased by further injection. 
Case and technique presentation: An 84-year-old male patient with hemiparalysis after brain 
infarction developed a submandibular lymphnode metastasis from oral floor cancer. We 
injected gel into the submucosal and subcutaneous space surrounding the tumor to create a 
safe distance, and then delivered 18Gy (76.5GyE LQ2, α/┚ = 3) (Fig. 3). 
b. Reirradiation to retropharyngeal lymphnode metastasis (mucosal preservation) 
Background: Retropharyngeal node metastasis (RPNM) commonly occurs in the clinical 
course of head and neck cancers. The incidence of RPNM in oropharyngeal cancer has been 
reported as 27.5% [Gross, 2004], and post-surgical development of RPNM in 
hypopharyngeal cancer as 13.2% [Kamiyama, 2009]. This involvement has a significantly 
negative impact on the prognosis [Dirix, 2006], and there has been no safe and effective non-
invasive or minimally invasive treatment for recurrence after radiotherapy. 
Case and technique presentation: A left retropharyngeal lymph node (Rouviere’s node) 
metastasis was found in a 50-year-old man who complained of an abnormal sensation in his 
neck 1 year after left neck surgery for pharyngeal pouch cancer followed by 50 Gy of 
external beam radiotherapy. Despite chemotherapy, the tumor increased in size and the 
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symptoms worsened. The patient received reirradiation, as shown in Fig. 4, and has been 
healthy without any evidence of relapse for 4 years.  
 
(a) Submandibular tumour before treatment. (b) The created distance measures approximately 1 cm. 
Injected gel is contrast enhanced. 18 Gy was delivered in a single fraction. (c) Six months after the 
brachytherapy. 
Fig. 3. Skin and mucosal preservation in HDRBT by HGI. 
 
(a). An applicator needle (dotted line) was inserted from the left side of the neck (b) and a single dose of 20 
Gy (100% line) was prescribed (c). Part of the needle can be seen in the target. Note the higher-dose area at 
the target. The pharyngeal mucosa was shifted to the low-dose area following injection of hyaluronate 
during irradiation (thick arrow and ribbon). There is a remarkable decrease in FDG accumulation 2 months 
after the brachytherapy (d). This photograph has been published previously [Kishi, 2009]. 
Fig. 4. Reirradiation to retropharyngeal lymphnode metastasis. PET study reveals abnormal 
accumulation of FDG in the metastatic retropharyngeal lymphnode 
4.2 Abdominal/chest reirradiation 
Numerous sites can be treated with this technique: chest wall, abdominal wall, various 
metastatic lymph nodes, adrenal gland metastasis, and parenchymal lesions. To date, 
curative reirradiation to paraaortic lymphnode metastasis has been one of the most difficult 
to safely achieve. 
a. Reirradiation to paraaortic lymphnode metastasis:  
Background: Paraaortic lymph nodal (PALN) metastasis is a frequent clinical sequel in 
various abdominopelvic malignancies, including pancreatic cancer, for which the 
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rationale for surgery is limited [Pavlidis, 2011]. Eradicative PALN reirradiation would be 
ideal, but a safe dose is usually limited by surrounding radiosensitive organs, particularly 
the intestines. In reirradiation, the spinal cord and kidneys, as well as the intestines, may 
narrow the range of available beam angles. To date, only a few reports have described 
reirradiation in the abdomen, and these report the use of palliative doses [Chou, 2001; 
Haque, 2009].  
Case and technique presentation: We encountered a patient with pancreatic cancer who 
developed PALN metastasis as an in-field recurrence, 6 months after resection of pancreatic 
cancer with 50 Gy of preoperative radiotherapy. A single fraction of 18 Gy was delivered to 
the tumor (75.6 Gy equivalent in a conventional schedule calculated with the LQ model at 
┙/┚ = 2 for the small intestines) and a total estimated D2cc (the minimum dose to the most 
irradiated volume of 2 cc) in the small intestines of 58.5 GyE LQ2, /┚ = 3 with HGI; and 96 GyE 
LQ2,α/┚ = 3 without HGI. No complications were observed for 6 months. Three months after 
treatment, there was no FDG accumulation, tumor size had reduced, and the serum CA-19-9 
value decreased from 5150 to 36.6 U/mL (normal range, <37.5). We consider that this case 
conclusively demonstrates that brachytherapy with HGI procedure by the paravertebral 
approach is safe and effective in reirradiation of PALN recurrence. The dosimetric and 
technical details of this case are to be published in the Journal of Radiation Research [Kishi, 
2011b]. 
The paravertebral brachytherapy approach used in this case involved the application of a 
safe and reliable interventional procedure [Knelson, 1989] that is substantially unaffected by 
respiratory movement. This technique, under step-by-step X-ray CT guidance, achieved 
stable, precise needle deployment and gel injection. 
4.3 Pelvic tumors 
Also in the pelvic area, HDRBT with HGI may facilitate safe and effective reirradiation for 
recurrent primary lesions, lymph nodal or bone metastasis that have developed after 
radiotherapy to these areas [Kishi, 2011a] 
a. Reirradiation to recurrent prostate cancer 
In the treatment of prostate cancer, technological advancements in radiotherapy have 
enabled dose escalation to be performed safely. In intermediate- or high-risk prostate 
cancers, however, the reported local recurrence rate of 10%–30% remains high. A technique 
is required for further safe dose escalation for these refractory cancers, as well as a safe 
reirradiation technique for relapsed prostate cancer. Because the rectum is closely adjacent 
to the prostate, the radiotolerance limit of the rectum is generally lower than normal 
following curative external beam radiotherapy. 
According to a summary in a review [van Vulpen, 2011] 5-year biological disease-free 
survival in six studies on reirradiation of prostate cancer was approximately only one third 
following initial curative dose treatment, and the incidences of grade 3 toxicities in the 11 
studies on total 290 patients was approximately 4% of gastrointestinal toxicity and 14% of 
genitourinary toxicity, respectively. Further increase of toxicity should not be allowed in 
future attempts of dose escalation.  
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Fig. 5. Paravertebral approach and dose distribution. A small part of intestine was involved 
with more than 25% of the prescribed dose. Symbols: thick arrow, injected contrast-
enhanced gel; thin arrows, injection needles; double arrowheads, brachytherapy applicator 
needles; double thin arrows, the closest part of small intestine shifted by HGI; double dotted 
arrows, superimposed lines of the original position of the closest part of small intestine; and 
thick line with dots, tumor contour. The oblique injection needle was inserted to move the 
second closest part of the small intestine, which was shifted aside. Isodose curves are 25%, 
50%, 75%, 100% (asterisk), 125%, 150%, 200%, 250%, and 300%, in order from outermost to 
innermost. This figure taken from the original figures to be published in the Journal of 
Radiation Research [Kishi, 2011b]. 
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Fig. 6. Diagram showing the track of the injection needle to the injection point (dotted circle) 
in the anterior perirectal adipose tissue behind the rectal side of the rectovesical fascia 
(Denonvilliers’ fascia). Gel injected from this point (half-tone arrows) flows into the 
perirectal and pararectal spaces to encase the rectum. Abbreviations (in alphabetical order): 
Bl, bladder; peri, peritoneum; Pr, prostate; prf, perirectal fascia; R, rectum; rvf, rectovesical 
fascia (Denonvilliers’ fascia); Sv, seminal vesicle; vpf, vesicoprostatic fascia. 
Case and technique presentation: In a patient with local recurrence of prostate cancer at 18 
months after initial radiotherapy of 61.8 GyELQ2,α/┚ = 3 to the prostate, we prescribed 16 Gy 
(60.8 GyE LQ2,α/┚ = 3 or 78.2 GyELQ2,α/┚ = 1.6) of reirradiation HDRBT with HGI (Figs. 6, 7). The 
procedure was achieved in 10 minutes, without complications. Rectal D2cc for reirradiation 
was 5.6 Gy (9.58 GyELQ2,α/┚ = 3). Compared with the initial radiation, the gel injection 
resulted in an improved therapeutic ratio. The patient was regularly followed up at our 
clinic: at over 3.5 years after reirradiation there was no evidence of recurrence or radiation-
related toxicities greater than Grade 2, maintaining a nadir PSA level of 0.03 ng/ml without 
hormonal therapy. The details and treatment technique in this case have been reported in 
Brachytherapy [Kishi, 2011a]. 
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Fig. 7. Upper row: Reconstructed images of the rectum and the prostate for the initial (left) 
and reirradiation (right) brachytherapy (interval between dots on the prostate is 8 mm). 
Following gel injection, the rectum is shifted posteriorly and is reduced in size. 
Lower row: Dose distribution curves for the initial (left) and reirradiation (middle) 
brachytherapies. The rectum and prostate are separated more than 25 mm (measureable 
with the dot interval). Thin layers of air are seen in and along the perirectal fascia. The 
relative positions of the rectum and prostate are maintained even 4 hours after injection 
(right). Contrast medium was injected into the rectum. The figures were form the original 
manuscript for that published in Brachytherapy [Kishi, 2011a]. 
5. Discussion 
5.1 Problems to be addressed in reirradiation treatment 
5.1.1 Hypoxic environment of reirradiation target 
Strong hypoxia in recurrent tumor after irradiation: Tumors larger than a certain size (>0.1 
mm) usually develop hypoxic areas due to insufficient vascular supply. These areas are also 
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a sanctuary from hydrophilic chemotherapeutic agents, although launching waves of attacks 
may be effective. Cellular adaption to hypoxia includes cell cycle arrest and resulting 
prolongation of repair deadlines, increased capability of anaerobic glycolysis resulting in 
lactic acid pooling, and cellular immigration programs towards more oxygen rich 
environments producing actins and losing cadherins. Previously irradiated tissue tends to 
be more hypoxic and therefore frequently more radioresistant. Popovtzer et al. reported 92% 
of the third recurrence was the in-field of the second irradiation (reirradiation), which 
occurred in 77% of median 68-Gy-reirradiated patients in 154 relapsed squamous head and 
neck cancer patients [Popovtzer, 2009]. This suggests much higher dose may be biologically 
required to overcome the reparability of recurrent tumor after initial radiotherapy. In this 
situation, HDRBT has the important advantage of providing high-dose areas close to the 
source inserted in the tumor. Furthermore, another possibility that an incomplete 
reirradiation may promote the immigration capability should be taken into account. 
5.1.2 Diagnostic jeopardy 
Precise judgment of a diagnosis of recurrence can be difficult because of tissue hypoxia 
induced by the radiotherapy itself and the biological responses that occur in and around the 
irradiated area. Diagnostic features for tumor recurrence includes, 1) increase in tumor size 
(especially new nodule protrusion), 2) revascularization in the tumor (not static 
revascularization around the tumor), and 3) strong increase in FDG-PET accumulation. 
Swelling of the tumor, emergence of a ring enhancement zone, and persistent weak or 
moderate appearance of FDG-PET accumulation in or around the irradiated tumor are often 
observed in reactive inflammatory phenomena, or tumor-related. Currently recommendable 
approach to make a differential diagnosis in these situations is only to rationally integrate 
and interpret the time course of PET-CT, enhanced MR, and MR diffusion imaging findings 
as well as the biological nature of the tumor cells as well as post-irradiation changes of 
involved normal tissues.  
5.1.3 Occurrence of complications 
In our previous report of reirradiation with a total accumulated target dose of 125.6 Gy 
(median)[Kishi, 2009], the actual incidence of complications was very low (0% directly 
related to the radiotherapy) than expected (16.1%) over a 19.5-month observation period. 
This may have occurred because we had created a sufficient safety margin in the gel spacing 
procedure, and because of the time interval from the previous radiation effect. 
5.1.4 The problem of equivalent dose calculation 
The LQ model may overestimate a single high-dose effect: the LQ model is well validated, 
experimentally and theoretically, allegedly up to approximately 10 Gy/fraction, and is 
reasonable for clinical use up to a large dose of about 18 Gy per fraction in fractionated 
schedules [Brenner, 2008]. Recent studies revealed the significant overestimation of large 
single-dose treatment effect calculated by the LQ model, in both clinical and experimental 
data [Astrahan, 2008; Iwata, 1984; Kirkpatrick, 2008]. Overestimation of the single high-dose 
effect tends to be greater in a dose larger than DT = 2 x (/ ratio) [Astrahan, 2008]. In the 
LQL model, a linear function works over the range of DT Gy. The LQL model is currently 
under evaluation.  
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5.1.5 Interval repair 
An interval of more than 6 months was considered to increase spinal tolerance level [Nieder, 
2005; 2006]. Several authors reported the effectiveness of reirradiation by external beam 
[Okamoto, 2002; Oksuz, 2004; Sulman, 2008; Wu, 2007; Wurschmidt, 2008] with a relatively 
small incidence of grade 3–4 toxicity for a cumulative dose of 110–117 Gy, where the median 
intervals ranged from 13 to 92 months. However we must be careful to apply some idea of 
interval repair because an individual tissue tolerance differs not only by the dose and the 
interval. 
5.2 Injectable material 
1. Artificial cross-linked hyaluronate: There are long-lasting variants of hyaluronate that 
are artificially cross-linked and resistant to biodegration, some of which are durable for 
months (Restylane SubQ, Q-med, Uppsala, SWEDEN)[Restylane®-International] and 
are used as a filler by subcutaneous injection in cosmetic augmentations. Unlike native-
type hyaluronate, no biological research, including the receptor-mediated process, is 
available for this variant. Use of this type of hyaluronate was reported by Prada et al. 
for creating and maintaining a space during IMRT, HDRBT, and LDRBT for prostate 
cancer [Prada, 2007, 2009]. In response, Vordermark et al. proposed that a material with 
a faster resolution would be suitable for application to HDRIBT [Vordermark, 2008]. 
These long-lasting hyaluronate implants may cause immune [Hamilton, 2007] or 
inflammatory reactions [Arron, 2007], or infections [Christensen, 2009] [Arron, 2007; 
Edwards, 2007; Ghislanzoni, 2006; Wiest, 2009; Wolfram, 2006], and have been 
surgically removed from some patients [Arron, 2007; Edwards, 2007; Ghislanzoni, 2006; 
Wiest, 2009; Wolfram, 2006].  
2. Dextrose solution: Dextrose solution is one of the most commonly used spacers. The low 
viscosity of the fluid makes it difficult to create an effective durable space, meaning that a 
large dose is generally required. A previous study reported that 625 ml (range, 250–1,200 
mL) of 5% dextrose in water was required to separate organs (by approximately 1 cm 
according to the published figures) during radiofrequency ablation [Arellano, 2010]. 
Electrolyte imbalance and fluid overload must be carefully monitored in this situation. 
5.3 Time and cost-effectiveness of the present method 
The cost of native-type high-molecular-weight hyaluronate is US$10–US$15 for a 2.5 ml (2.5 
mg) vial, which is approximately one-sixtieth the cost of the artificially cross-linked durable 
type. The time required to complete the procedure is 10–15 minutes in most cases; thus, HGI 
is highly time- and cost-effective. 
5.4 Further possibilities 
As well as its use for creating a safe distance, or enabling curative radiotherapy that has 
been impossible until now, HGI has potential for further development. This spacing method 
will safely guide ｔhe insertion of larger therapeutic devices and/or organs without 
requiring an intensive surgical procedure. This technique has the potential to affect a 
profound shift in the manner in which physicians consider retreatment options for 
previously irradiated tissue, in a manner hitherto unknown. 
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6. Summary and conclusion 
6.1 Background 
In this chapter we describe a technical solution for problems associated with reirradiation. 
Radiotherapy is singularly effective in cancer control, even in a second treatment 
(reirradiation). Sufficient dose delivery may promise a local cure, but reirradiation is usually 
limited due to the tolerance level of surrounding normal tissue. 
6.2 Method 
To safely perform high-dose reirradiation treatment, our radiation oncologists and 
interventional radiologists cooperated to develop a novel procedure based on a recent 
advance in molecular science. Our aim was to create a safe distance in critical radiotherapy 
by injecting native-type high-molecular-weight hyaluronic acid between the target and 
organs at risk under ultrasound or X-ray CT guidance. The procedure is termed hyaluronic 
gel injection (HGI). The material protects tissues from injury and inflammation, and is 
reported in recent studies to inhibit cell migration and proliferation mediated by surface 
receptors including CD44. The injection is a quick and minimally invasive procedure 
performed with a 21-gauge needle, which, unlike surgery, enables a stepwise or fractionated 
schedule of outpatient treatment for multiple lesions. 
During the period that the created distance is maintained by the injected gel, typically a few 
hours, a single-session irradiation is performed by high-dose-rate brachytherapy (HDRBT) 
with CT-based 3D planning. We reported that this injection procedure provides a significant 
reduction in normal tissue complication probability (NTCP) in various situations, enabling 
doses ranging from 15 to 20 Gy to be safely delivered to the target without significantly 
involving surrounding at-risk organs. 
6.3 Result 
The biological equivalent dose for the dose range was 50.4–92 Gy for a conventional 
radiotherapy schedule at ┙/┚ = 3, fulfilling the individual dose requisition for each curative 
purpose. In comparative analysis of our clinical records, we found that the therapeutic ratio 
(TR) of target dose to risk-organ dose was increased by approximately three times by this 
HGI procedure. To the best of our knowledge, other than that for surgery, this enhancement 
factor of TR is the largest value found to date. In our published report of 30 patients with 
recurrent cancer after 60 Gy (median) of previous external beam treatment, reirradiation by 
HDRBT with HGI resulted in distinct tumor shrinkage in 95%; and significant pain 
reduction, and Grade 2 or larger early and late toxicity in 95%, 85%, and 0%, respectively, 
during the 19.5-month observation period. To date, we have reported reirradiation in cases 
of paraaortic lymphnode metastasis, recurrent lung cancer, uterine cancer, prostate cancer, 
and head and neck cancer, among others, with long-lasting curative effect. 
6.4 Conclusion 
This risk-organ-sparing preservation procedure offers safe and efficient reirradiation 
treatment for recurrent cancer patients, in terms of longstanding local cancer control 
without significant physical stress, as well as providing pain reduction. 
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